Ironwood and Allergan Report Topline Phase IIb Data Supporting Further Investigation of Linaclotide Colonic Release-2 (CR2) for Abdominal Pain in Non-Constipation Subtypes of IBS
https://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-and-Allergan-Report-Topline-Phase-IIb-Data-Supporting-Further-Investigation-of-Linaclotide-Colonic-Release-2-CR2-for-Abdominal-Pain-in-Non-Constipation-Subtypes-of-IBS/default.aspx
Ironwood and Allergan Report Topline Phase IIb Data Supporting Further Investigation of Linaclotide Colonic Release-2 (CR2) for Abdominal Pain in Non-Constipation Subtypes of IBS
https://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-and-Allergan-Report-Topline-Phase-IIb-Data-Supporting-Further-Investigation-of-Linaclotide-Colonic-Release-2-CR2-for-Abdominal-Pain-in-Non-Constipation-Subtypes-of-IBS/default.aspx
Ironwood and Allergan Report Topline Phase IIb Data Supporting Advancement of Linaclotide Colonic Release-1 (CR1) in IBS-C
https://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-and-Allergan-Report-Topline-Phase-IIb-Data-Supporting-Advancement-of-Linaclotide-Colonic-Release-1-CR1-in-IBS-C/default.aspx
Ironwood and Allergan Report Topline Phase IIb Data Supporting Advancement of Linaclotide Colonic Release-1 (CR1) in IBS-C
https://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-and-Allergan-Report-Topline-Phase-IIb-Data-Supporting-Advancement-of-Linaclotide-Colonic-Release-1-CR1-in-IBS-C/default.aspx
Ironwood Pharmaceuticals Announces Approval of LINZESS® (linaclotide) in Japan for the Treatment of Adults with IBS-C
https://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Pharmaceuticals-Announces-Approval-of-LINZESS-linaclotide-in-Japan-for-the-Treatment-of-Adults-with-IBS-C/default.aspx
Ironwood Pharmaceuticals Announces Approval of LINZESS® (linaclotide) in Japan for the Treatment of Adults with IBS-C
https://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Pharmaceuticals-Announces-Approval-of-LINZESS-linaclotide-in-Japan-for-the-Treatment-of-Adults-with-IBS-C/default.aspx
Ironwood Highlights ZURAMPIC® (lesinurad) Phase III Extension Study Data at the American College of Rheumatology 2016 Annual Meeting
https://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Highlights-ZURAMPIC-lesinurad-Phase-III-Extension-Study-Data-at-the-American-College-of-Rheumatology-2016-Annual-Meeting/default.aspx
Ironwood Highlights ZURAMPIC® (lesinurad) Phase III Extension Study Data at the American College of Rheumatology 2016 Annual Meeting
https://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Highlights-ZURAMPIC-lesinurad-Phase-III-Extension-Study-Data-at-the-American-College-of-Rheumatology-2016-Annual-Meeting/default.aspx
Ironwood Pharmaceuticals to Present at Stifel 2016 Healthcare Conference
https://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Pharmaceuticals-to-Present-at-Stifel-2016-Healthcare-Conference/default.aspx
Ironwood Pharmaceuticals to Present at Stifel 2016 Healthcare Conference
https://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Pharmaceuticals-to-Present-at-Stifel-2016-Healthcare-Conference/default.aspx